Hanmi exports combo drug to overseas markets

Published: 2009-07-24 06:56:00

Updated: 2009-07-24 06:56:00

Local drug maker Hanmi Pharm said on July 20 that it will export its independently developed incrementally modified drug (IMD) to overseas markets through a multinational pharmaceutical company.

The company said on July 21 that Amosartan, which combines amlodipine camsylate with losartan, will...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK